Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.
PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.
In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.
Recent Achievements and Current Projects
- Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
- Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
- Expansion of global reach through new product launches tailored to various market needs.
PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.
Revvity (NYSE: RVTY) has announced the launch of the EURORealTime APOE assay, an in-vitro diagnostic test for APOE genotyping in European countries accepting the CE mark. This test is important for assessing a patient's risk of side effects before starting anti-amyloid therapy for Alzheimer's disease.
The assay allows simultaneous detection of the three most frequent APOE forms (E2, E3, and E4), with E4 carriers having the highest risk for ARIA (Amyloid-Related Imaging Abnormalities) under therapy. The test requires only one reaction using genomic DNA from a single blood sample and can be automated on Revvity instruments, including the EUROIMMUN PreNAT II and chemagic 360 platforms.
This new solution will enable clinicians to take a more personalized approach in anti-amyloid treatment for Alzheimer's patients by providing additional patient information through APOE genotyping.
Revvity (NYSE: RVTY) has announced its participation in two upcoming investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 4, with CFO Max Krakowiak speaking at 8:45 a.m. ET. Additionally, Revvity will attend the 2024 Baird Global Healthcare Conference in New York City on September 10, where Steve Willoughby, SVP of investor relations, ESG, and risk, will present at 12:15 p.m. ET.
Both presentations will provide updates on Revvity's strategic priorities and will be available via live audio webcasts on the company's website. Replays will be accessible for at least 30 days after the events on the Revvity Investor Relations website.
Revvity reported Q2 2024 financial results with revenue of $692 million, down 2% reported and 1% organic. GAAP EPS was $0.45, up from $0.28 year-over-year, while adjusted EPS from continuing operations was $1.22, slightly up from $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80.
Segment performance varied: Life Sciences revenue decreased 7% to $314 million, with adjusted operating margin at 35.8%. Diagnostics revenue increased 1% to $378 million, with adjusted operating margin improving to 25.9%. Revvity updated its full-year revenue guidance to $2.77-$2.79 billion, assuming 2% organic growth.
Revvity's Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. This dividend will be paid on November 8, 2024, to shareholders of record at the close of business on October 18, 2024. Revvity, traded on the New York Stock Exchange under the ticker symbol RVTY, continues its practice of rewarding shareholders through regular dividend payments. This announcement demonstrates the company's commitment to providing consistent returns to its investors, even as it navigates the current economic landscape.
Revvity (NYSE: RVTY) will announce its Q2 2024 financial results on July 29, 2024, before the market opens. A conference call hosted by CEO Prahlad Singh and CFO Max Krakowiak will follow at 8:00 a.m. ET to discuss the results. Investors can access the live audio webcast via the company's website.
Revvity (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on June 10, 2024, at 8:00 a.m. ET in Miami, FL. The event will feature Prahlad Singh, the president and CEO of Revvity, who will provide an update on the company's strategic priorities. A live audio webcast and a replay of the presentation will be available on the company's website.
Revvity, Inc. (NYSE: RVTY) reported financial results for the first quarter ended March 31, 2024, revealing a (4)% reported growth and a (3)% organic growth in revenue, with GAAP EPS of $0.21, compared to the same period last year. Adjusted EPS was $0.98, reaffirming full year 2024 organic growth and adjusted EPS guidance. It's important to note that the company's adjusted operating income and profit margins have decreased compared to the same period last year. The company will provide a live webcast on April 29, 2024, to discuss the results.
FAQ
What is the market cap of PERKINELMER (PKI)?
What does PerkinElmer Inc. do?
What is the mission of PerkinElmer Inc.?
How many employees does PerkinElmer Inc. have?
What was PerkinElmer Inc.'s revenue in 2020?
In how many countries does PerkinElmer Inc. serve customers?
What are some of PerkinElmer Inc.'s recent achievements?
How does PerkinElmer Inc. contribute to healthcare?
Is PerkinElmer Inc. part of any major stock index?
What markets does PerkinElmer Inc. serve?
What is a core focus of PerkinElmer Inc.'s partnerships?
